VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
According to the company, the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing VERAXA with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026.
The full press release is available at https://ibn.fm/QiPhH. VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
Forward-looking statements in this release involve risks and uncertainties, as detailed in the company's SEC filings. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
